Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on discovering and developing medicines using an integrated artificial intelligence–driven drug discovery platform. The company operates at the intersection of biotechnology, machine learning, and automation, aiming to industrialize drug discovery by systematically mapping biology at scale. Its core strategy is to identify novel therapeutic candidates more efficiently than traditional approaches by combining high-throughput experimental biology with advanced computational models.
The company’s primary revenue drivers currently include drug discovery and development programs, strategic partnerships, and collaboration agreements with large pharmaceutical companies. Recursion primarily targets diseases with high unmet medical need, including rare genetic diseases, oncology, and fibrotic and neurodegenerative disorders. Founded in 2013, the company evolved from an academic-driven biology platform into a publicly traded company following its IPO in 2021, progressively expanding its technology stack, data assets, and clinical pipeline.
Business Operations
Recursion’s operations are organized around its integrated Recursion Operating System, which combines automated wet-lab experimentation, large-scale biological and chemical datasets, and proprietary machine learning models. The company generates revenue through a mix of internal pipeline advancement and external partnerships that provide upfront payments, research funding, and potential milestone and royalty payments. Its internal programs advance through preclinical and clinical development, with several candidates in Phase 1 and Phase 2 trials.
The company conducts the majority of its laboratory and computational operations domestically while supporting international clinical trials and research collaborations. Recursion controls extensive proprietary biological datasets, high-throughput imaging infrastructure, and AI-enabled predictive models. Major partnerships include collaborations with Roche, Bayer, and NVIDIA, which provide both capital and access to complementary technologies. Its primary operating subsidiary is Recursion Pharmaceuticals LLC, which holds the core research and development activities.
Strategic Position & Investments
Recursion’s strategic direction centers on scaling its platform to map biological relationships across genes, proteins, pathways, and compounds, enabling faster and more cost-effective drug discovery. Growth initiatives include expanding its clinical pipeline, increasing automation capacity, and deepening AI capabilities through advanced computing infrastructure. The company has made significant investments in data generation and computational resources to support long-term platform scalability.
Notable acquisitions include Valence Discovery, which enhanced Recursion’s deep learning capabilities for chemical space exploration. The company has also invested heavily in high-performance computing, including a strategic collaboration with NVIDIA to develop AI supercomputing infrastructure for biological modeling. Emerging focus areas include generative AI for drug design and multi-disease network biology, though the commercial impact of these technologies remains in development.
Geographic Footprint
Recursion is headquartered in Salt Lake City, Utah, which serves as the central hub for its research, automation, and corporate operations. The company maintains additional offices and research presence in Toronto, Canada, largely stemming from its AI-focused acquisitions and talent base. These locations support both experimental biology and computational research.
While its physical footprint is concentrated in North America, Recursion has a global operational influence through international clinical trials and partnerships with multinational pharmaceutical companies. Its collaborations extend across North America, Europe, and parts of Asia, reflecting a globally oriented development and commercialization strategy despite a limited number of owned international facilities.
Leadership & Governance
Recursion was co-founded by Chris Gibson, who continues to shape the company’s long-term vision of data-driven drug discovery. Leadership emphasizes a platform-first philosophy, prioritizing scalable technology, cross-disciplinary integration, and long-term value creation over single-asset development. Governance reflects a blend of biotech, technology, and capital markets expertise.
Key executives include:
- Chris Gibson – Co-Founder and Chief Executive Officer
- Ben Mabey – Co-Founder and Chief Scientific Officer
- David Hallett – Chief Legal Officer and Secretary
- Najat Khan – Chief R&D Officer
- Michael Secora – Chief Financial Officer
The leadership team’s strategic vision centers on transforming drug discovery into a predictable, data-driven engineering discipline while maintaining rigorous clinical and regulatory standards.